Bio-Techne (BSP:T1CH34) Short-Term Debt : R$0 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Bio-Techne Short-Term Debt?

Bio-Techne's Short-Term Debt for the quarter that ended in Dec. 2023 was R$0 Mil.

Bio-Techne's annual Short-Term Debt increased from Jun. 2021 (R$63 Mil) to Jun. 2022 (R$63 Mil) but then declined from Jun. 2022 (R$63 Mil) to Jun. 2023 (R$0 Mil).

Bio-Techne Short-Term Debt Historical Data

The historical data trend for Bio-Techne's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne Short-Term Debt Chart

Bio-Techne Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Short-Term Debt

Get a 7-Day Free Trial

48.20

64.86

62.86

63.10

Bio-Techne Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Bio-Techne Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Bio-Techne Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Bio-Techne's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Techne (BSP:T1CH34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (BSP:T1CH34) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

TECH:USA TE1:Germany

Address

614 McKinley Place N.E., Minneapolis, MN, USA, 55413

Website

https://www.bio-techne.com

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Bio-Techne (BSP:T1CH34) Headlines

No Headlines